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Abstract. Monkeypox virus (MPXV), a zoonotic orthopoxvirus (OPX), is endemic in the Democratic Republic of
Congo (DRC). Currently, diagnostic assays for human monkeypox (MPX) focus on real-time quantitative polymerase
chain reaction (PCR) assays, which are typically performed in sophisticated laboratory settings. Herein, we evaluated
the accuracy and utility of a multiplex MPX assay using the GeneXpert platform, a portable rapid diagnostic device
that may serve as a point-of-care test to diagnose infections in endemic areas. The multiplex MPX/OPX assay
includes a MPX-specific PCR test, OPX-generic PCR test, and an internal control PCR test. In total, 164 diagnostic
specimens (50 crusts and 114 vesicular swabs) were collected from suspected MPX cases in Tshuapa Province, DRC,
under national surveillance guidelines. The specimens were tested with the GeneXpert MPX/OPX assay and an OPX
PCR assay at the Institut National de Recherche Biomedicale (INRB) in Kinshasa. Aliquots of each specimen were
tested in parallel with a MPX-specific PCR assay at the Centers for Disease Control and Prevention. The results
of the MPX PCR were used as the gold standard for all analyses. The GeneXpert MPX/OPX assay performed at
INRB had a sensitivity of 98.8% and specificity of 100%. The GeneXpert assay performed well with both crust and
vesicle samples. The GeneXpert MPX/OPX test incorporates a simple methodology that performs well in both labora-
tory and field conditions, suggesting its viability as a diagnostic platform that may expand and expedite current MPX
detection capabilities.
INTRODUCTION
Monkeypox virus (MPXV) is a zoonotic orthopoxvirus
(OPX) endemic to west and central Africa. Each year, major-
ity of human monkeypox (MPX) infections are reported
from the Congo Basin in the Democratic Republic of Congo
(DRC).1,2 Since 2005, laboratory-confirmed cases of MPX
have also been reported from Republic of the Congo, Central
African Republic, Sudan,3–5 Sierra Leone (unpublished
data, US Centers for Disease Control and Prevention), and
Cameroon (unpublished data, World Organization of Animal
Health). Serologic evidence of OPX infection in Sierra Leone
suggests human exposure to wild-type zoonotic OPXs in
west Africa.6 Although smallpox vaccination with Vaccinia
virus provides protection against human MPXV infection,7
lack of routine vaccination after smallpox eradication in 1980
has been hypothesized to have contributed to an increase in
human MPX incidence.8,9
MPXV is transmitted to humans from a primary zoonotic
source, and the virus is also capable of human-to-human
transmission.10 The animal reservoir of MPXV remains
unknown; however, several genera of African rodents
(Cricetomys, Graphiurus, Funiscirurus) have been identified
as potential reservoirs responsible for transmission and
maintenance of the virus.11,12 Contact with wildlife, which
often occurs in rural communities in DRC that are depen-
dent on bushmeat as a protein source, is thought to
increase risk for human infection with MPXV.13
Human infection with MPXV can lead to a smallpox-like ill-
ness with an 11% fatality rate in unvaccinated individuals.14
Upon infection, the estimated incubation period is on aver-
age 7–14 days, but can range from 5 to 21 days. The
disease is characterized by a prodrome of fever, chills, head-
ache, and myalgia lasting 1–3 days, followed by a maculo-
papular eruption. The median of number of days from onset
of fever to onset of rash is about 2 days. The rash pro-
gresses slowly over a 2- to 3-week period, evolving through
vesicular and pustular stages, and culminating in crusts.14–17
At the earliest stages of illness—prior to advanced rash
lesion differentiation—MPX can be difficult to discriminate
from other rash illnesses such as varicella.18 In DRC, over
2,000 cases of suspected MPX are reported to the Ministry
of Health annually, but only a subset of those cases are
formally investigated with laboratory confirmation of diag-
nostic specimens.
Molecular diagnostics for human MPX are currently limited
to real-time quantitative polymerase chain reaction (qPCR)
assays in specialized laboratory settings.19 Delayed clinical
diagnosis and lack of etiologic confirmation (via laboratory
testing) are impediments to controlling the spread of MPX.
Increased diagnostic capabilities in areas at risk for MPX
would allow for an efficient and timely public health response
in the case of an outbreak. Therefore, a relatively simple
system designed to perform well in less sophisticated labo-
ratories and field conditions would aid in surveillance and
disease control activities.
The Cepheid GeneXpert system is a backpack-sized, con-
solidated analytic workstation that combines sample prepa-
ration with real-time PCR amplification and detection. The
system uses a self-contained cartridge to minimize con-
tamination risks, and results are obtained from minimally
processed samples in less than 90 minutes. This technology
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has been used for the detection of a number of infectious
diseases, most notably Mycobacterium tuberculosis with
rifampicin resistance, methicillin-resistant Staphylococcus
aureus, and, most recently, Ebola virus disease (EVD).20–22 In
this study, we evaluated the accuracy and utility of a multi-
plex MPXV and OPX assay using the GeneXpert platform, to
provide an alternative to traditional PCR detection methods.
METHODS
Surveillance methods and specimen collection. In
2010, the U.S. Centers for Disease Control and Prevention
(CDC) and the Kinshasa School of Public Health (KSPH)
began a program with the DRC Ministry of Health to
enhance surveillance for human MPX in Tshuapa Province
(formerly Tshuapa District in Equateur Province). The popula-
tion of Tshuapa Province is approximately 1.6 million per-
sons, and 600–900 cases of suspected MPX are reported
from the province each year. Procedures for enhanced
surveillance included completion of an MPX-specific case
investigation form and collection of at least one diagnostic
specimen from ill persons who met the clinical criteria speci-
fied in the suspected MPX surveillance case definition—an
illness characterized by vesicular pustular eruption with well-
circumscribed, deep-seated lesions and at least one of the
following symptoms: fever preceding the eruption, lymphade-
nopathy (inguinal, axillary, and/or cervical), and/or pustules or
crusts on the palms of the hands or soles of the feet.
Lesion specimens collected for diagnosis were 1) vesicu-
lar or pustular lesion fluid, collected by touching the tip of a
sterile Dacron swab to the lesion; 2) lesion crusts, collected
by using the blunt end of a sterile tool to dislodge a crust;
and/or 3) vesicular or pustular lesion roof, collected using
the blunt end of the sterile tool to dislodge the friable outer
surface of the lesion (Figure 1). All specimens were stored
in a sterile tube at 4°C. Specimens and case investigation
forms were transferred to the national laboratory, Institut
National de Recherche Biomedicale (INRB), in Kinshasa.
As an addendum to routine testing, patients (or family
proxy) were asked by Ministry of Health–designated surveil-
lance personnel to consent to having limited additional test-
ing performed on the diagnostic specimens. This study
received ethical approval from institutional review boards at
the CDC and KSPH.
Specimen preparation. Crust and vesicular swab speci-
mens were processed for testing and storage at INRB.
Swab specimens were hydrated in 1.5 mL of phosphate-
buffered saline (PBS) and then spun on a benchtop micro-
centrifuge for 30 seconds, after which the supernatant was
eluted. Crust specimens were first homogenized in 0.5 mL
of PBS solution, then an additional 1.0 mL of PBS was
added, and the sample was spun on a benchtop centrifuge
for 30 seconds to settle particulate matter. For each sample
type, approximately 1.5 mL of supernatant was produced.
For each specimen, 100 μL of supernatant was used for
the MPX/OPX GeneXpert assay and 100 μL was used for
DNA extraction (Qiagen EZ1 DNA Tissue Kit, Germantown,
MD) and real-time OPX PCR at INRB.23 Additionally, 800 μL
of the supernatant from each specimen was sent to the CDC
for independent testing and validation, where 100 μL was
used for a duplicate GeneXpert assay and 100 μL was
used for DNA extraction and real-time MPX-generic PCR. At
CDC, DNA was extracted from the supernatant using the
EZ1 DNA Tissue Kit (Qiagen) in conjunction with the EZ1
platform (Qiagen).
All steps requiring specimen manipulation, including
swab processing, crust homogenization, elution in PBS, and
transfer to the GeneXpert cartridge were conducted within a
certified biosafety cabinet.
MPX-generic real-time PCR assay (gold standard).
Determination of the presence of MPXV DNA was accom-
plished using a real-time MPX-“generic” PCR assay with
primers and fluorescent probes specifically designed for
MPXV detection. The assay targeted the G2R region within
the tumor necrosis factor receptor gene, and was capable of
detecting all known strains of MPXV (hence, the use of the
term “generic” to describe the assay). The assay was
performed as previously described on the ABI 7500 DX Fast
Real-Time PCR Instrument (Applied Biosystems, Foster City,
CA) for 40 cycles, and specimens were run in duplicate.24
Results were assessed using existing clinical guidelines,24
which provided threshold cycle (Ct) value cutoffs for positive
(< 37), indeterminate (37–39), and negative test results (0 or
40). Because indeterminate results did not result in a positive
diagnosis, they were grouped with the negative results for
the analyses in this study.
GeneXpert MPX/OPX assay. The GeneXpert MPX/OPX
assay uses specialized cartridges for sample preparation and
multiplex real-time PCR. The reagents were prepared before-
hand in the form of lyophilized cakes and were packaged
within the GeneXpert cartridge. This MPX/OPX assay was
developed collaboratively with BioGX (Birmingham, Alabama),
who aided in custom lyophilized real-time PCR reagent
manufacturing, packaging of the real-time PCR reagents into
the GeneXpert cartridges, design and performance optimiza-
tion of the multiplex assay, and development and programing
of the GeneXpert extraction and run protocols.
FIGURE 1. Unroofing of a pustular lesion during specimen col-
lecion (photo credit: A. McCollum).
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The primers for the MPX and OPX assays, G2R_G and E9L
NVAR, respectively, were used as previously described.24,25
The limit of detection for the OPX assay was previously deter-
mined to be 2.56 fg of DNA or 12.5 genome copies on
another platform.25 The assay utilized fluorescent labeled
TaqMan® style nuclease probes for the detection of the
amplified targets. The probes used in the assay were labeled
as follows: 6-carboxyfluorescein for the detection of MPXV,
CalFluor Red 610 for the detection of OPX, and Cy5 for the
detection of the internal amplification control (IAC). The three
fluorophores have sufficient separation in both their excita-
tion and emission spectra to allow for efficient multiplexing
on the GeneXpert platform.
The MPX/OPX multiplex assay utilizes a spiked IAC to
mitigate the false-negative reporting which could occur due
to extraction of PCR-inhibiting substances from the sample
matrix. The IAC contains synthesized DNA fragments that
are not similar to known DNA sequences of any living
organism; the IAC is a proprietary component of the car-
tridge. The IAC is an important reference for interpretation
of negative and indeterminate results. The IAC template is
limited to a low, but reliably amplifiable level, to allow effi-
cient amplification with minimal effect on the reporting of
the MPX and OPX targets in positive samples.
For sample preparation, 100 μL of the supernatant was
combined with 600 μL of PBS and mixed before it was
transferred to the sample-loading cartridge chamber. In addi-
tion, 1 mL of distilled water was added to a water-loading
cartridge chamber. At INRB, cartridges were loaded onto
a GeneXpert IV (Cepheid, Sunnyvale, CA) and operated
according to manufacturer’s instructions. At the CDC, either
a GeneXpert IV or GeneXpert II platform was used.
Results for the MPX- and OPX-specific assays were
assessed using the same criteria and Ct value cutoffs for
clinical diagnosis as the MPX-generic real-time PCR assay.24
The possible assay outcomes and interpretation of results
are listed in Table 1.
Protocol change. During the first round of specimen
testing (November 2012–May 2013), it was found that the
GeneXpert platform repeatedly experienced failed runs
when assays were performed on crust samples. The error
message displayed “Syringe pressure of n PSI exceeds the
protocol limit of m PSI” (n and m referring to software pres-
sure values). We hypothesized that, due to the particulate
matter generated from pulverization of crust samples, the
needle in the GeneXpert instrument became clogged,
resulting in failed runs due to excessive syringe pressure.
In February 2014, several changes were made during initial
specimen preparation steps performed at INRB (as
described above). An extra crust homogenization step was
added, as well as an extra centrifugation step to decrease
particulate matter. The results from both before and after
the protocol change were analyzed; crust specimens that
produced an error message were not subjected to a new
preparation and reanalyzed.
Data analysis. The goal of this study was not only to
compare the performance of the GeneXpert platform to the
PCR gold standard, but also to ensure that the GeneXpert
compared well under natural conditions at the national lab-
oratory in DRC. Therefore, we compared GeneXpert results
from both the CDC and INRB to the results of the MPX-
generic real-time PCR assay run at the CDC. Finally, for a
relative comparison to existing capabilities, we also com-
pared the results of the INRB OPX PCR assay results to
those of the gold standard.
All data analyses were conducted using SPSS version
21.0 (Chicago, IL).
RESULTS
Characteristics of specimens. In total, 164 specimens
were collected from 161 suspected MPX cases (79 males
and 82 females). The median age of patients was 16 years
(range was 0 to 79 years); 72 specimens (45%) were col-
lected from adults, and 89 (55%) were collected from children
(< 18 years). Of these specimens, 50 (30%) were crusts and
114 (70%) were vesicular swabs (Table 2).
Eighty-eight (55%) specimens were positive for the pres-
ence of MPXV DNA signatures via MPX-generic real-time
PCR assay conducted at the CDC. An additional 60 (37%)
specimens were negative, and 13 (8%) yielded indetermi-
nate results. Combining the negative and indeterminate
categories, 73 (45%) specimens were classified as negative
for purposes of the analyses that follow.
Specimen timeline. Specimens were collected from
patients with active illness through the enhanced disease
TABLE 1
Array of possible results using the GeneXpert multiplex assay for MPX detection*
GeneXpert test interpretation MPX assay OPX assay IAC assay
MPX positive Positive Positive Positive/negative*
MPX negative Negative Positive/negative Positive/negative
OPX positive Positive/negative Positive Positive/negative
MPX, OPX negative Negative Negative Positive
Negative through inhibition Negative Negative Negative
IAC = internal amplification control; MPX = monkeypox, OPX = orthopoxvirus.
*In multiplex assays, reaction components are shared competitively between separate polymerase chain reaction tests in the multiplex. The IAC template is limited to a low, but reliably
amplifiable level to test for sample quality and inhibition for MPX- and OPX-negative cases. However, in samples of poor quality (demonstrated by high MPX and/or OPX assay Ct values),
the IAC may amplify though still yielding a MPX- and/or OPX-positive test result.
TABLE 2








< 18 89 41
≥ 18 72 47
Specimen type†
Crust 50 25
Vesicular swab 114 63
*Cases with at least one specimen tested positive for monkeypox using a monkeypox-
generic real-time polymerase chain reaction assay (gold standard) at the Centers for
Disease Control and Prevention.
†A total of 164 specimens were collected from 161 cases.
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surveillance system. The patients who participated in this
study reported developing a rash after a mean of 2.5 days
(range was −7 to 33 days) post-illness onset. Patients
received care from a health-care worker after an average of
5.8 days post-rash onset (range was −6 to 30 days), at
which time a case investigation was performed and speci-
mens were collected. After specimen collection, it took an
average of 44.1 days (range, 10 to 207 days) for the speci-
men to be received at the national laboratory in Kinshasa.
Sixty-five percent of specimens were tested 1 month or
longer after specimen collection and about 10% of the spec-
imens were tested 2 months or greater after specimen col-
lection. There were no differences in MPX-positive versus
negative specimens between the average time of collection
to specimen arrival in Kinshasa (45.98 days versus 41.96
days [two-sample t-test, P value = 0.117], respectively)
(Table 3).
Performance of the GeneXpert MPX/OPX assay. When
compared with the MPX-generic real-time PCR assay gold
standard, the sensitivity of the GeneXpert MPX/OPX test
conducted at INRB was 98.8% (83/84) and the specificity
was 100% (65/65). The positive predictive value (PPV) was
100% (83/83) and negative predictive value (NPV) was
98.5% (64/66). The sensitivity of the GeneXpert MPX/OPX
test conducted at CDC was 98.6% (74/75) and the speci-
ficity was 100% (71/71). The PPV for the CDC GeneXpert
MPX/OPX test was 100% (74/74) and the NPV was 98.6%
(71/72).
With respect to specimen type, crusts and vesicles per-
formed similarly on the GeneXpert platform at both INRB
and CDC (Table 4). For example, crust samples tested at
the INRB yielded a sensitivity of 100% (23/23) and a speci-
ficity of 100% (20/20), whereas vesicular swabs gave a sen-
sitivity of 98.4% (60/61) and a specificity of 100% (45/45).
During the first round of specimen testing (November
2012–May 2013), the GeneXpert platform experienced diffi-
culties in processing crust samples: 23%(7/30) of crust
specimens tested at the INRB and 47% (14/30) of those
tested at the CDC demonstrated at least one failed run and
required further testing. After protocol changes were insti-
tuted in February 2014, only 5% (7/134) of specimens
tested at the INRB and 3% (4/134) of those tested at the
CDC experienced failed runs.
At INRB, the standard for MPXV testing was a generic
OPXV real-time PCR assay. When compared with the MPX-
generic real-Time PCR assay gold standard, the OPXV
assay had a sensitivity of 72.7% (64/88) and a specificity of
82.3% (51/62) (Table 4).
Ct values for specimens using the MPX-generic real-time
PCR assay gold standard were compared with positive Ct
values obtained from the GeneXpert platforms at INRB or
CDC (from the same specimens). The mean, median, mini-
mum, and maximum Ct values were comparable across
platforms and instruments.
MPX/OPX multiplex assay efficiency. When multi-
plexing, the PCR efficiency can be negatively affected due to
competition between the separate PCR tests in the multi-
plex, as well as, the increased consumption and sharing of
reaction components compared with simplex reactions.
Both the MPX and OPX assays were previously validated in
simplex with efficiencies of 90% and 83%, respectively.24,25
In multiplex, the MPX assay had an efficiency of 95%, and
OPX had an efficiency of 91% (data not shown); thus, effi-
ciency was observed to increase when the simplex tests
were multiplexed together.
DISCUSSION
The GeneXpert MPX/OPX assay displayed high sensitiv-
ity, specificity, NPV, and PPV in specimens from suspect
cases. The assay was highly accurate regardless of the
type of specimen collected (crust versus vesicular swab),
the place of testing (INRB or CDC), and demonstrated the
ability to identify MPX infection at any stage of the rash.
Blood viremia after MPXV infection is often time dependent
and unreliable for acute diagnosis,5 so crust and vesicular
swab specimens were preferable, and also reduced the risks
associated with needle use for the patients. Further, crusts
and vesicular swabs were used for their reliability and stabil-
ity with the GeneXpert cartridge.
The initial deployment of the GeneXpert platform required
some initial trial and error to determine optimal cartridge
TABLE 3
Timeline of MPX symptoms to specimen receipt at the National Laboratory (number of days)
Fever to rash Rash to specimen collection Specimen collection to laboratory
MPX positive MPX negative MPX positive MPX negative MPX positive MPX negative
Mean 2.2 2.9 5.4 6.0 46.0 42.0
Median 2.0 2.0 5.0 5.0 39.0 40.0
Range −5.0 to 9.0 −7.0 to 33.0 −6.0 to 23.0 0.0 to 30.0 10.0 to 207.0 12.0 to 185.0
MPX = monkeypox.
TABLE 4
Performance of assays in relation to the MPX-generic real-time PCR assay (gold standard) by specimen type
Crusts (N = 50) Vesicles (N = 114)
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
INRB MPX/OPX* GeneXpert 100 100 100 100 98.4 100 100 97.8
CDC MPX/OPX GeneXpert 100 100 100 100 98.3 100 100 97.6
OPX PCR 68.0 92.0 89.5 74.2 74.6 85.4 79.7 68.6
CDC = Centers for Disease Control and Prevention; INRB = Institut National de Recherche Biomedicale; MPX = monkeypox; NPV = negative predictive value; OPX = orthopoxvirus;
PCR = polymerase chain reaction; PPV = positive predictive value.
*MPX/OPX refers to the monkeypox/orthopoxvirus multiplex assay run on the GeneXpert platform.
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preparation procedures to minimize the number of failed
runs. The initial, relatively high rate of failed runs is hypothe-
sized to have been due to the large amount of particulate
matter generated during the pulverization of crusts, which
could have clogged the needle instrument. The specimen
processing procedures were modified slightly, which sharply
decreased the number of failed runs. Training to trouble-
shoot and interpret GeneXpert protocols is necessary to
optimize performance.
An important advantage of the GeneXpert system as a
diagnostic platform for testing of specimens suspected of
harboring OPXV is that only minimal sample manipulation is
needed prior to loading the specimen into the cartridge. This
both increases the safety for the person performing the test
and reduces contamination risks, especially during DNA
extraction steps. Although the closed reaction chamber sig-
nificantly reduces contamination after the test cartridge has
been prepared, potential contamination during specimen
processing steps could lead to erroneous results. Surfaces
and tools used to process specimens should be extensively
cleaned and decontaminated to avoid contamination with
foreign DNA. Furthermore, reducing the number and difficulty
of steps for specimen preparation has the additional benefit
of reducing the need for highly trained operators to conduct
the test, though training in laboratory safety and molecular
diagnostic techniques is still recommended.
In DRC, human MPX diagnostics are currently limited to
real-time PCR in a specialized reference laboratory located
in Kinshasa. In this study, the average time for a specimen
to be delivered to the national laboratory after collection
was about a month and a half. The current long turnaround
time between specimen collection and testing hinders the
ability to implement effective public health safety measures
and infection control practices in the event of an MPX out-
break. In this study, the assay still performed well despite
the large turnaround times, which is a testament to a com-
bination of the stability of MPX specimens and robust per-
formance parameters of the GeneXpert platform. However,
positioning a GeneXpert machine closer to the point of case
detection could accelerate diagnosis to within days of case
detection, leading to quicker disease management, taking
advantage of the safety and ease which allows for its ability
of decentralized testing.
Currently, costs associated with the GeneXpert system
and its cartridges may constitute a barrier to more wide-
spread use. The cost for a GeneXpert machine—with four
modules—is currently about USD 60,000 (two module, USD
40,000), and each MPX/OPX assay cartridge costs approxi-
mately USD 75. Compared with traditional real-time PCR,
which costs about USD 5–10 per test, lower costs for the
GeneXpert cartridges will be required for broader use of this
test for routine diagnostics. However, multiplexing provides
a way to reduce reaction costs by as much as 40%. The
cost of a multiplex reaction is close to that of a singleplex
reaction, so performing multiplex reactions offers savings
when compared with performing three singleplex reactions
independently, for example.
Another consideration for rural field settings is the need
for a reliable power source for the GeneXpert. In Tshuapa
Province, for example, power sources are limited, which
would limit its use for bedside diagnosis. However, since
the GeneXpert platform is being used for diagnostics for
other infectious diseases, most notably EVD and tuberculo-
sis, the ability to implement this assay where the technol-
ogy is already being used may increase the feasibility of the
test where human MPX and these other infectious diseases
overlap. Newer versions with increased portability and bat-
tery life may also become available soon, overcoming some
current limitations.
Overall, we found the GeneXpert MPX/OPX test to be a
specific and accurate test for detecting human MPX infec-
tion. Compared with traditional real-time PCR diagnostic
methods, it is not only easier and much faster to use, but
also offers lower risk of contamination and increases user
safety through its all-in-one cartridge system. This study
highlights the importance of optimizing detection parameters
for qPCR tests to create versatile, but specific multiplex
assays that may succeed in both specialized laboratory envi-
ronments and field conditions. Analytical results provided
by the GeneXpert MPX/OPX test, in conjunction with other
pertinent clinical and epidemiological data may provide a
promising alternative to current laboratory diagnostic capa-
bilities in diagnosing MPX infection in suspected cases.
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